GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today announced that cell and gene therapy pioneer Claudia Zylberberg, PhD has been appointed as an independent board member and senior advisor of its Morgenesis LLC ("Morgenesis") point-of-care (POCare) subsidiary. As founder, board member and former CEO of Akron Bio, Dr. Zylberberg has led Akron Bio to its leadership position among makers of cGMP-compliant ancillary materials, novel products, and tools for advanced and regenerative medicines. She is also a member of the Strategic Advisory Council for the International Society for Cell & Gene Therapy, sits on the boards for Canada's CCRM and the Standards Coordinating Body (SCB) for Regenerative Medicine, and is co-founder and board chair of ARScience Biotherapeutics, a clinical developer of immunomodulators.

"We're very proud to have Claudia join us to guide Morgenesis as it redefines the possibilities for delivering POCare therapies," said Vered Caplan, CEO of Orgenesis. "Her insights, based on over three decades of experience in the cell therapy space, will be critical as we assist companies and hospitals endeavoring to bring cell therapies to more patients, producing them wherever they are needed."

"Morgenesis is uniquely situated to bring both novel technologies, like the Orgenesis Mobile Processing Units and Labs ('OMPULs'), and a range of POCare Services in the U.S. and across the globe," said Dr. Zylberberg. "Cell and gene therapies show promise as real, durable cures for a range of challenging diseases, and I look forward to helping Morgenesis enable potential life-saving treatments for more patients."

Earlier this month, Morgenesis secured additional funding from Metalmark Capital Partners ("Metalmark"), bringing the total investment from Metalmark to $35 million since November 2022.

About Orgenesis
Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. .

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform and OMPUL business, our ability to achieve and maintain overall profitability, our ability to manage our research and development programs that are based on novel technologies, our ability to control key elements relating to the development and commercialization of therapeutic product candidates with third parties, the timing of completion of clinical trials and studies, the availability of additional data, outcomes of clinical trials of our product candidates, the potential uses and benefits of our product candidates, our ability to manage potential disruptions as a result of the COVID-19 pandemic, the sufficiency of working capital to realize our business plans and our ability to raise additional capital, the development of our POCare strategy, our trans differentiation technology as therapeutic treatment for diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to further our CGT development projects, either directly or through our JV partner agreements, and to fulfill our obligations under such agreements, our license agreements with other institutions, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products, risks relating to legal proceedings against us and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

IR contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021
Orgs@crescendo-ir.com

Communications contact for Orgenesis
IB Communications
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
neil@ibcomms.agency / michelle@ibcomms.agency